Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TransTech Pharma has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment, H3 receptor antagonists, PPAR delta agonists, and 11 beta HSD1 inhibitors.
Subscribe to our email newsletter
TransTech made an undisclosed one-time payment to Novo Nordisk for acquisition of the programs.
Adnan Mjalli, TransTech’s founder, chairman and CEO, said: “We are extremely pleased to have prevailed in the acquisition process and to add these programs to our robust diabetes and obesity portfolio. We are confident that all three programs represent promising approaches to addressing unmet medical needs. These additions to the pipeline will allow TransTech to become a world leader in the discovery and development of novel treatments for diabetes, obesity and other metabolic disorders.”